Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Global Blood Therapeutics Inc (NASDAQ: GBT) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Global Blood Therapeutics Inc (NASDAQ: GBT) concerning whether a series of statements by Global Blood Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On September 13, 2018, an article published by Stat about Global Blood, claimed that there are “important risks that investors might be glossing over” about the likelihood of Global Blood’s new drug for sickle cell disease, voxelotor. The article cited the results of a recent Phase 3 clinical trial and stated “Global Blood lacks data demonstrating voxelotor reduces the frequency of crises,” which is traditionally a necessary criterion for FDA approval of a sickle cell disease treatment. In addition, the article stated that, “[i]n the Phase 3 study, voxelotor did not improve the quality of life of sickle cell patients.”

Following this news, NASDAQ: GBT fell over 7.4% to close at $42.55 per share on September 13, 2018.

Based in South San Francisco, California, and founded in 2011 Global Blood Therapeutics engages in the discovery, development, and delivery of treatments for underserved patient communities.

If you purchased shares of Global Blood Therapeutics Inc (NASDAQ: GBT) on or before September 13, 2018, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185